Effient

Product manufactured by Eli Lilly And Company

Application Nr Approved Date Route Status External Links
NDA022307 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Effient ® Is A P2y 12 Platelet Inhibitor Indicated For The Reduction Of Thrombotic Cardiovascular Events (including Stent Thrombosis) In Patients With Acute Coronary Syndrome Who Are To Be Managed With Pci As Follows: Patients With Unstable Angina Or Non-St-Elevation Myocardial Infarction (nstemi) ( 1.1 ). Patients With St-Elevation Myocardial Infarction (stemi) When Managed With Either Primary Or Delayed Pci ( 1.1 ). 1.1 Acute Coronary Syndrome Effient ® Is Indicated To Reduce The Rate Of Thrombotic Cardiovascular (cv) Events (including Stent Thrombosis) In Patients With Acute Coronary Syndrome (acs) Who Are To Be Managed With Percutaneous Coronary Intervention (pci) As Follows: Patients With Unstable Angina (ua) Or Non-St-Elevation Myocardial Infarction (nstemi). Patients With St-Elevation Myocardial Infarction (stemi) When Managed With Primary Or Delayed Pci. Effient Has Been Shown To Reduce The Rate Of A Combined Endpoint Of Cardiovascular Death, Nonfatal Myocardial Infarction (mi), Or Nonfatal Stroke Compared To Clopidogrel. The Difference Between Treatments Was Driven Predominantly By Mi, With No Difference On Strokes And Little Difference On Cv Death [see Clinical Studies ( 14 )] .

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Prasugrel Hydrochloride PRASUGREL HYDROCHLORIDE ZINC35653007

Comments